计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
B125576-1mg |
1mg |
现货 ![]() |
| |
B125576-5mg |
5mg |
现货 ![]() |
| |
B125576-10mg |
10mg |
现货 ![]() |
| |
B125576-25mg |
25mg |
现货 ![]() |
| |
B125576-50mg |
50mg |
现货 ![]() |
| |
B125576-100mg |
100mg |
现货 ![]() |
|
英文别名 | SMR004702826 | BDBM50503350 | EX-A2032 | NCGC00346693-01 | Apigenin, 13 | SCHEMBL15757461 | HMS3655J09 | MFCD22420825 | BCP9000425 | SW219166-1 | (4-butoxy-2H-pyrazolo[3,4-b]pyridin-5-yl)-(2,6-difluoro-4-methylphenyl)methanone | s2014 | BRD-K62814476-001- |
---|---|
规格或纯度 | Moligand™, ≥95% |
英文名称 | BMS-265246 |
生化机理 | 强大的细胞周期蛋白依赖性激酶1(cdk1)和cdk 2抑制剂(IC50值分别为5.6-71和6-14 nM)。还抑制亚 微摩尔范围内的cdk4和cdk5以及低微摩尔范围内的cdk7和cdk9。在体外抑制HCT-116结肠癌细胞的增殖。BMS-265246 is an ATP site-targeting, potent and CDK1/2-selective cyclin-dependent kinase inhibitor (IC50 = 6 nM/CDK1, 9 nM/CDK2, 230 nM/CDK4) with anti-cancer efficacy in A2780 ovarian cancer culture (IC50 = 760 nM). |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 抑制剂 |
作用机制 | 细胞周期蛋白依赖性激酶 1 抑制剂;细胞周期蛋白依赖性激酶 2 抑制剂 |
产品介绍 |
BMS-265246是一种有效的选择性CDK1/2抑制剂,无细胞试验中IC50为6 nM/9 nM。作用于CDK1/2 比作用于CDK4选择性高25倍。 |
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 504773261 |
---|---|
分子类型 | 小分子 |
IUPAC Name | (4-butoxy-2H-pyrazolo[3,4-b]pyridin-5-yl)-(2,6-difluoro-4-methylphenyl)methanone |
INCHI | InChI=1S/C18H17F2N3O2/c1-3-4-5-25-17-11(8-21-18-12(17)9-22-23-18)16(24)15-13(19)6-10(2)7-14(15)20/h6-9H,3-5H2,1-2H3,(H,21,22,23) |
InChi Key | SCFMWQIQBVZOQR-UHFFFAOYSA-N |
Canonical SMILES | CCCCOC1=C(C=NC2=NNC=C12)C(=O)C3=C(C=C(C=C3F)C)F |
Isomeric SMILES | CCCCOC1=C(C=NC2=NNC=C12)C(=O)C3=C(C=C(C=C3F)C)F |
PubChem CID | 135402864 |
分子量 | 345.34 |
溶解性 | 溶于DMSO, 最高浓度 (mg/mL): 17.27, 最高浓度(mM): 50 |
---|---|
分子量 | 345.300 g/mol |
XLogP3 | 3.900 |
氢键供体数Hydrogen Bond Donor Count | 1 |
氢键受体数Hydrogen Bond Acceptor Count | 6 |
可旋转键计数Rotatable Bond Count | 6 |
精确质量Exact Mass | 345.129 Da |
单同位素质量Monoisotopic Mass | 345.129 Da |
拓扑极表面积Topological Polar Surface Area | 67.900 Ų |
重原子数Heavy Atom Count | 25 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 456.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
Purity(HPLC) | 95-100(%) |
---|---|
NMR spectrum | Conforms to Structure |
Appearance(B125576) | white to beige to pink powder |
1. Sutherland JJ, Low J, Blosser W, Dowless M, Engler TA, Stancato LF. (2011) A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators.. Mol Cancer Ther, 10 (2): (242-54). [PMID:21216932] [10.1021/op500134e] |